Produktbild: Selective COX-2 Inhibitors

Selective COX-2 Inhibitors Pharmacology, Clinical Effects and Therapeutic Potential

Fr. 137.00

inkl. gesetzl. MwSt., Versandkostenfrei


Beschreibung

Produktdetails

Einband

Taschenbuch

Erscheinungsdatum

05.11.2012

Herausgeber

Sir John R. Vane + weitere

Verlag

Springer Netherland

Seitenzahl

150

Maße (L/B/H)

24/16/1 cm

Gewicht

274 g

Auflage

Softcover reprint of the original 1st ed. 1998

Sprache

Englisch

ISBN

978-94-010-6041-7

Beschreibung

Portrait

Sir John Vane is the Director General at the William Harvey Research Institute, an independent charitable foundation within Queen Mary and Westfield College of the University of London, UK.

Sir John Vane shared the Nobel Prize in Physiology or Medicine in 1982 for his discoveries of the mechanism of action of aspirin and of prostacyclin, as well as his work on other prostanoids. Jack Botting is Consultant at the William Harvey Research Institute, an independent charitable foundation within Queen Mary and Westfield College of the University of London, UK.

Produktdetails

Einband

Taschenbuch

Erscheinungsdatum

05.11.2012

Herausgeber

Verlag

Springer Netherland

Seitenzahl

150

Maße (L/B/H)

24/16/1 cm

Gewicht

274 g

Auflage

Softcover reprint of the original 1st ed. 1998

Sprache

Englisch

ISBN

978-94-010-6041-7

Herstelleradresse

Springer-Verlag KG
Sachsenplatz 4-6
1201 Wien
AT

Email: GPSR Kontakt

Noch keine Bewertungen vorhanden

Verfassen Sie die erste Bewertung zu diesem Artikel

Helfen Sie anderen Kundinnen und Kunden durch Ihre Meinung.

Kundinnen und Kunden meinen

Bewertungen (0)

  • Produktbild: Selective COX-2 Inhibitors
  • Preface. 1. Mechanism of Action of Anti-Inflammatory Drugs: An Overview; J.R. Vane, R.M. Botting. 2. The Structure of Human COX-2 and Selective Inhibitors; M.F. Browner. 3. Differential Inhibition of COX-1 and COX-2 by NSAIDs: A Summary of Results Obtained Using Various Test Systems; M. Pairet, et al. 4. COX-2 in Brain and Retina: Role in Neuronal Survival; N.G. Bazan, et al. 5. COX-2 and Apoptosis: NSAIDs as Effectors of Programmed Cell Death; D.L. Simmons, et al. 6. Inhibition of Intestinal Tumorigenesis via Selective Inhibition of COX-2; R.N. DuBois, et al. 7. Cyclooxygenase Enzymes in Human Vascular Disease; C. Patrono, et al. 8. Gastrointestinal Effects of NSAIDs; C.J. Hawkey. 9. Renal Side-Effects of NSAIDs: Role of COX-1 and COX-2; J.C. Frolich, D.O. Stichtenoth. 10. Aspirin-Induced Asthma and Cyclooxygenases; R.J. Gryglewski. 11. New Classification of Aspirin-like Drugs; H. Fenner. 12. New Highly Selective COX-2 Inhibitors; A.W. Ford-Hutchinson. 13. Specific COX-2 Inhibitors: From Bench to Bedside; P. Isakson, et al. 14. Meloxicam: Selective COX-2 Inhibition in Clinical Practice; D.E. Furst. Index.